Gerald Murphy has practiced in the intellectual property field since 1977 and has prosecuted thousands of patent applications in the areas of biotechnology, biopharmaceuticals, therapeutic antibodies, organic chemistry, biochemistry and pharmaceuticals. Mr. Murphy has also handled a number of appeals within the U.S. Patent and Trademark Office. He has presented oral arguments before the U.S. Board of Patent Appeals and Interferences and the Patent Trial and Appeal Board (PTAB) on a number of occasions and has represented clients in a variety of post grant matters, including inter partes reviews, interferences and reexaminations. He has personally participated in over 35 patent interferences and trials before the PTAB, including related appeals to the Court of Appeals for the Federal Circuit.
Mr. Murphy has counseled clients and prepared numerous opinions analyzing patent validity and infringement issues, managed worldwide patent portfolios and lectured before international audiences on U.S. patent law. Mr. Murphy served as the sole arbitrator in two arbitrations involving patent and licensing issues in the fields of DNA diagnostics and therapeutic monoclonal antibodies and has served as an expert witness in patent infringement litigations and an arbitration involving a patent license agreement.
Mr. Murphy started BSKB’s yearly Summer Patent Seminar in 1983 and chaired the seminar until 2016. Mr. Murphy currently chairs BSKB’s annual Post Grant Bootcamp, a 3-day course covering all PTO proceedings affecting issued U.S. patents.
Genzyme Therapeutic Prods. Ltd. v. BioMarin Pharma. Inc. [IPR Nos. 2013-00534 and -00537] 825 F.3d. 1360 (Fed. Cir. 2016) – Enzyme Replacement Therapy for Pompe Disease
BioMarin Pharma., Inc. v. Duke Univ., IPR2013-00535, Paper 86 (PTAB Feb. 23, 2015), Duke Univ. v. BioMarin Pharm., Inc., 685 F.App’x 967 (Fed. Cir. Apr. 25, 2017), and BioMarin Pharm., Inc. v. Duke Univ., IPR2013-00535, Paper 92 (PTAB Jan. 17, 2018)– Enzyme Replacement Therapy for Pompe Disease
Chen (Mayo) v. Freeman (Dana-Farber) and Chen (Mayo) v. Kingsbury (Dana-Farber), Interference Nos. 105,872, 105,884, 105,885, 105,887 and 105,901, Decision on Priority, February 19, 2014 (PTAB 2014) – DNA, Protein and Antibodies related to Progammed Death-Ligand 1 (PD-L1)
1984, Virginia, U.S. Court of Appeals for the Federal and Fourth Circuits and U.S. District Court, Eastern District of Virginia
Registered to practice before the U.S. Patent and Trademark Office
University of Maryland (B.S., Microbiology, 1976)
George Mason University School of Law (J.D., 1984)
George Washington University National Law Center (LL.M., highest honors, 1989)